logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
返回期刊详情
P

Pharmacoeconomics-Open

IF2.1
论文数53
被引数
期刊论文 53
发表时间
delete
Updated Health Economics Simulation Model of the Lifetime Progression of Multiple Sclerosis in an Australian Setting更新后的澳大利亚背景下多发性硬化症终生进展的健康经济学模拟模型
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deletePalmer, Andrew J.; Zhao, Ting; Henson, Glen; Ahmad, Hasnat; Taylor, Bruce V.; van der Mei, Ingrid; Campbell, Julie A.
delete分享
delete收藏
Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies非洲不良药物反应成本与研究报告质量：一项关于疾病经济负担研究的系统综述
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deleteKebede, Bezie; Bahiru, Bereket; Tafere, Chernet
delete分享
delete收藏
Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis与双膦酸盐相比，生物类似药地诺单抗治疗绝经后骨质疏松症的成本效益
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete1
deleteOAAI
deleteFlanigan, Jeanine; Kane, Sarah; Fashami, Fatemeh Mirzayeh; Zhou, Anna; Almuallem, Lamees; Tindal, Mike; Schauf, Marion; Li, Edward; Lyman, Gary H.
delete分享
delete收藏
Estimating Eligibility for Lung Cancer Screening in Ireland: A Dynamic Modelling Study of Smoking Trends评估爱尔兰肺癌筛查资格：一项关于吸烟趋势的动态建模研究
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deleteBezdenezhnykh, Tatiana; O'Mahony, James F.; Jacob, Benjamin M.; Redmond, Patrick
delete分享
delete收藏
Trial-Based Economic Evaluations Conducted alongside Studies Embedded in Australian Healthcare Services and Programs: A Scoping Review在澳大利亚医疗保健服务与项目中进行并嵌入研究的试验为基础的经济评估：范围综述
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deleteWang, Belinda; Sherrington, Catherine; Pivotto, Luiza R.; Saputra, Stanley; Comachio, Josielli; Scarfe, Joanne; Szewczyk, Zoe; Costa, Nathalia; Pearce, Alison; Hassett, Leanne; Milat, Andrew; Williams, Christopher; Kwok, Wing S.; Yu, Justin; Howard, Kirsten; Pinheiro, Marina B.
delete分享
delete收藏
Economic Burden of Spinal Muscular Atrophy in Singapore: A Societal Perspective Cost-of-Illness Study新加坡脊髓性肌萎缩症的经济负担：一项基于社会角度的疾病成本研究
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deleteLim, Zhi Zhen; Lim, Yan Ling; Wang, Furene Sijia; Ling, Simon Robert; Tay, Stacey Kiat Hong; Wang, Yi
delete分享
delete收藏
Advancing Lost Productivity Measurement in Economic Evaluations: Evidence Priorities from a Targeted Literature Review and Expert Workshop推动经济学评价中生产率损失测量的进展：基于目标文献综述和专家研讨会的证据优先事项
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deleteMcQueen, R. Brett; Cohen, Benjamin; Kacergis, Caroline; Kennedy, Eileen; Rosettie, Katherine L.
delete分享
delete收藏
A Micro-costing Study of Community-Based Primary HPV Self-Sampling and Triage Test for Cervical Cancer Screening in Rural Cambodia农村柬埔寨社区为基础的HPV自我采样及宫颈癌筛查分层检测的微成本研究
deletePharmacoeconomics-Open
IF2.1
delete2026-05-01
delete0
deleteOAAI
deleteZhang, Ziyue; Bussmann, Hermann; Vong, Sathiarany; Kol, Hero; von Knebel Doeberitz, Magnus; De Allegri, Manuela; Singh, Kavita
delete分享
delete收藏
Prediction Error in Quality-Adjusted Life Years in Economic Evaluations of Immune Checkpoint Inhibitors: A Comparison Based on Projected and Observed Updated Survival免疫检查点抑制剂经济评估中质量调整生命年预测误差：基于预期与更新观察生存数据的比较
deletePharmacoeconomics-Open
IF2.1
delete2026-05-01
delete0
deleteOAAI
deleteChen, Jinyu; Zhang, Yichen; Han, Kexin; Han, Sheng; Shi, Luwen; Guan, Xiaodong
delete分享
delete收藏
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? (mar, 10.1007/s41669-026-00642-1, 2026)西班牙中重度克罗恩病序贯治疗策略的成本效益分析：生物类似药乌司奴单抗应如何定位？
deletePharmacoeconomics-Open
IF2.1
delete2026-05-01
delete0
PREAI
deleteRodriguez-Lago, Iago; Peinado-Fabregat, Jose Ignacio; Guigini, Marcelo; Cerezales, Monica; Ibanez, Francisco; Crespo, Carlos; Barreiro-de Acosta, Manuel
delete分享
delete收藏
Exploring the Sensitivity of Utilities Predicted by theEQ-5D, SF-6D, HUI3, 15D, AQoL-4D, and AQoL-8D Multi-Attribute UtilityInstruments to SF-36 Dimensions探讨EQ-5D、SF-6D、HUI3、15D、AQoL-4D和AQoL-8D多属性效用工具预测的效用值对SF-36维度的敏感性
deletePharmacoeconomics-Open
IF2.1
delete2026-05-01
delete0
deleteOAAI
deleteTetteh, Josephine N. A.; Schlander, Michael
delete分享
delete收藏
Validation of the Obesity Lifecycle Model Built to Assess the Cost Effectiveness of Novel Therapies in the Management of Obesity构建肥胖生命周期模型以评估肥胖管理中新疗法成本效益的验证
deletePharmacoeconomics-Open
IF2.1
delete2026-05-01
delete0
PREAI
deleteModley, Ben; Seddik, Ahmed; Evans, Marc; Stephens, Stephanie; Salter, Chloe; Appierto, Marilena
delete分享
delete收藏
Health Utilities Associated with Pneumococcal Diseases in Children and Adults: A Targeted Literature Review and Meta-analysis儿童和成人肺炎链球菌疾病相关健康效用：一项针对性文献综述和荟萃分析
deletePharmacoeconomics-Open
IF2.1
delete2026-04-01
delete0
PREAI
deleteHuang, Min; Romdhani, Hela; Song, Yan; Xie, Jipan; Sundaresan, Sanjana; Liu, Daisy; Rowen, Donna; Elbasha, Elamin H.; Mohanty, Salini; Kelly, Matthew S.
delete分享
delete收藏
Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France法国辅助生殖技术中，控制性卵巢刺激时，注射用 follitropin delta 与 follitropin alfa 和 follitropin beta 的成本效益比较
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete0
PREAI
deleteHamamah, Samir; Carette, Jeremy; Leleu, Henri; Markert, Marie
delete分享
delete收藏
Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal葡萄牙老年人群中佐剂重组带状疱疹疫苗的成本效益
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete0
PREAI
deleteZarkadoulas, Eleftherios; Silva, Fabio; Alves, Joana; Madeira, Francisco; Postma, Maarten J.
delete分享
delete收藏
Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis (jan, 10.1007/s41669-025-00612-z, 2026)美国杜氏肌营养不良症增量疾病负担（医疗成本和资源）：一项匹配队列分析
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete0
PREAI
deleteScavina, Mena; Posner, Nate; Dorling, Patricia; Talaga, Anna; Stachel, Anna; Alvir, Jose
delete分享
delete收藏
Prevalence and Healthcare Costs of Metabolic Disorders Among Individuals with Schizophrenia Following Initiation of Oral Antipsychotic Therapy精神分裂症患者口服抗精神病药物治疗启动后代谢障碍的患病率及医疗成本
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete0
PREAI
deleteTkacz, Joseph; Cajigal, Alejandro; Sidovar, Matthew; Wilson, Kathleen; Pennington, Emma; Okunev, Ilya; Gillard, Kristin
delete分享
delete收藏
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?西班牙中重度克罗恩病序贯治疗策略的成本效益分析：生物类似药乌司奴单抗应如何定位？
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete1
PREAI
deleteRodriguez-Lago, Iago; Peinado-Fabregat, Jose Ignacio; Guigini, Marcelo; Cerezales, Monica; Ibanez, Francisco; Crespo, Carlos; Acosta, Barreiro-de
delete分享
delete收藏
Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States在美国治疗新生血管性年龄相关性黄斑变性（nAMD）中，法瑞西单抗相对于阿柏西普的成本-效用分析
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete0
PREAI
deleteBaljoon, Ahmead; Diaby, Vakaramoko; Suther, Sandra; Dutton, Matthew; Ali, Askal; Eljilany, Islam
delete分享
delete收藏
Valuing Maintenance of Visual Function in Retinitis Pigmentosa: A Discrete Choice Experiment with Patients and the General Public视网膜色素变性患者视觉功能维持的价值评估：一项涉及患者和普通公众的离散选择实验
deletePharmacoeconomics-Open
IF2.1
delete2026-02-01
delete0
deleteOAAI
deleteMarsh, Kevin; Trapali, Myrto; Ingham, Mike; Martin, Silas
delete分享
delete收藏